New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:13 EDTZIOPZiopharm trial reaches target number of progression-free survival events
ZIOPHARM Oncology announced that the Phase 3, PICASSO 3, trial of palifosfamide in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the Independent Data Monitoring Committee. The company will announce topline results from this trial during the last week of March, it said. The company said, "Reaching the target number of progression events for PICASSO 3 positions us one step closer to understanding palifosfamide's full potential for this significant unmet medical need. With a positive study outcome, palifosfamide has the potential to become the first new treatment option in nearly 30 years for patients with first-line metastatic soft tissue sarcoma."
News For ZIOP From The Last 14 Days
Check below for free stories on ZIOP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
11:03 EDTZIOPZiopharm presents anti-tumor effects of Ad-RTS-mIL-12
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use